VestGen Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$236K Sell
2,426
-33
-1% -$3.1K 0.01% 913
2026
Q2
$220K Sell
2,459
-2
-0.1% -$165 0.01% 992
2026
Q1
$204K Sell
2,461
-149
-6% -$12K 0.01% 998
2025
Q4
$214K Sell
2,610
-2,074
-44% -$160K 0.01% 708
2025
Q3
$327K Sell
4,684
-20
-0.4% -$1.35K 0.01% 579
2025
Q2
$313K Sell
4,704
-346
-7% -$21.4K 0.01% 499
2025
Q1
$320K Buy
+5,050
New +$340K 0.01% 448

Other funds holding PBE

VestGen Advisors's PBE Position: Q3 2026 in Review

VestGen Advisors reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 1.3% in Q3 2026, selling an estimated $3.1K and leaving 2,426 shares worth $236K. The position accounts for 0.01% of the portfolio, ranked #913.

VestGen Advisors first reported a position in PBE in Q1 2025 and has held it in 7 quarters since. The position peaked at $327K in Q3 2025. 122 funds tracked by Wall St. Rank hold PBE as of Q3 2026.

  • VestGen Advisors held 2,426 shares of Invesco Biotechnology & Genome ETF worth $236K as of Q3 2026.
  • VestGen Advisors sold 33 Invesco Biotechnology & Genome ETF shares in Q3 2026, an estimated $3.1K.
  • Invesco Biotechnology & Genome ETF made up 0.01% of VestGen Advisors's portfolio in Q3 2026, its #913 holding.
  • VestGen Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q1 2025 and has held it in 7 quarters since.
  • VestGen Advisors's Invesco Biotechnology & Genome ETF position peaked at $327K in Q3 2025.
  • 122 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q3 2026.

Based on VestGen Advisors's 13F filing for Q3 2026, filed 27 Oct 2026.